Angiomotin: An Angiostatin Binding Protein That Regulates Endothelial Cell Migration and Tube Formation by Troyanovsky, Boris et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/2001/03/1247/8 $5.00
The Journal of Cell Biology, Volume 152, Number 6, March 19, 2001 1247–1254
http://www.jcb.org/cgi/content/full/152/6/1247 1247
 
Angiomotin: An Angiostatin Binding Protein That Regulates Endothelial 
Cell Migration and Tube Formation
 
Boris Troyanovsky, Tetyana Levchenko, Göran Månsson, Olga Matvijenko, and Lars Holmgren
 
Center for Genomics Research and Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 76 Stockholm, Sweden
 
Abstract. 
 
Angiostatin, a circulating inhibitor of angiogen-
esis, was identiﬁed by its ability to maintain dormancy of
established metastases in vivo. In vitro, angiostatin inhibits
 
endothelial cell migration, proliferation, and tube for-
mation, and induces apoptosis in a cell type–speciﬁc
 
manner. We have used a construct encoding the kringle
domains 1–4 of angiostatin to screen a placenta yeast
 
two-hybrid cDNA library for angiostatin-binding
peptides. Here we report the identiﬁcation of angiomotin,
a novel protein that mediates angiostatin inhibition of mi-
gration and tube formation of endothelial cells. In vivo,
angiomotin is expressed in the endothelial cells of
capillaries as well as larger vessels of the human pla-
centa. Upon expression of angiomotin in HeLa cells,
angiomotin bound and internalized ﬂuorescein-labeled
 
angiostatin. Transfected angiomotin as well as endoge-
nous angiomotin protein were localized to the leading
edge of migrating endothelial cells. Expression of an-
giomotin in endothelial cells resulted in increased cell
migration, suggesting a stimulatory role of angiomotin
in cell motility. However, treatment with angiostatin
 
inhibited migration and tube formation in angiomotin-
expressing cells but not in control cells. These ﬁndings
indicate that angiostatin inhibits cell migration by inter-
fering with angiomotin activity in endothelial cells.
Key words: endothelium • neovascularization • mi-
gration • plasminogen • receptor
 
Introduction
 
Angiogenesis is the process by which new capillaries are
formed by sprouting from preexisting vessels. It is a vital
function for the growth of normal tissues during embryo-
genesis as well as for the pathological growth of tumors
(Folkman, 1995). Direct evidence has shown that the
pathological proliferation of cancer cells will not result in a
proportional increase in mass without access to the blood
circulation. Tumors form their own circulatory system by
upregulating angiogenic stimulators and by downregulat-
ing angiogenesis inhibitors (Bouck et al., 1996; Hanahan
and Folkman, 1996).
The inability of seeded metastases to induce an angio-
genic response results in a dormant phenotype. This was
shown in a Lewis lung carcinoma model where the primary
tumor is angiogenic but also generates a circulating angio-
genesis inhibitor, angiostatin, that inhibits vascularization
of distant metastases (O’Reilly et al., 1994). Systemic
treatment with angiostatin maintains dormancy of these
metastases after the removal of the primary tumor. This
state of dormancy is characterized by a state of no expan-
sion where cell proliferation is balanced by an equal rate of
cell death (Holmgren et al., 1995; Parangi et al., 1996).
Angiostatin is a proteolytically derived fragment of plas-
minogen spanning the first four kringle domains (O’Reilly
et al., 1994). In mice, angiostatin inhibits primary tumor
growth as well as angiogenesis-dependent growth of me-
tastases (O’Reilly et al., 1994, 1996; Bergers et al., 1999).
In vitro, angiostatin inhibits endothelial cell migration and
reduces endothelial cell growth in proliferation assays; this
effect is specific for endothelial cells (Ji et al., 1998). Fur-
thermore, it has been shown that angiostatin induces en-
dothelial cell–specific apoptosis in vitro (Claesson-Welsh
et al., 1998; Lucas et al., 1998). This is a property shared
with other angiogenesis inhibitors such as thrombospon-
din and endostatin (Dhanabal et al., 1999; Jimenez et al.,
2000). In addition, angiostatin has been shown to inhibit in
endothelial invasion and tube formation in three-dimen-
sional in vitro angiogenesis assays (Barendsz-Janson et al.,
1998; Claesson-Welsh et al., 1998; Griscelli et al., 1998).
The in vitro activity of angiostatin in endothelial cell pro-
liferation assays resides in kringles 1–3, with kringle 1 be-
ing the most potent inhibitor and kringle 4 being relatively
ineffective (Cao et al., 1996). In addition, the kringle 5 do-
main of plasminogen has also been shown exhibit potent
anti-angiogenic activity (Cao et al., 1997).
The mechanisms by which angiostatin inhibits angiogen-
esis are still unclear. Moser et al. have demonstrated that
angiostatin binds to the 
 
a
 
/
 
b 
 
subunits of ATP synthase.
This mitochondrial protein was shown to bind angiostatin
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on the surface of endothelial cells and potentially inducing
H
 
1
 
 influx (Moser et al., 1999). Claesson-Welsh and co-
workers demonstrated that angiostatin upregulates focal
adhesion kinase (FAK)
 
1 
 
activity specifically in endothelial
cells and proposed that deregulation of FAK may result in
inhibition of migration and induction of apoptosis (Claes-
son-Welsh et al., 1998). In addition, the inhibition of an-
giogenesis in vivo is dependent on wild-type p53, as an-
giostatin does not inhibit angiogenesis in p53-null mice
(Jimenez et al., 2000).
We have used the yeast two-hybrid system to screen for
molecules that interact with angiostatin. Here we report
the identification of a novel angiostatin-binding protein
we named angiomotin (Latin motus 
 
5 
 
motility). We show
that angiomotin-transfected cells bind and respond to an-
giostatin by inhibition of cell migration and tube forma-
tion. These studies present evidence that angiomotin regu-
lates endothelial cell migration and tube formation.
 
Materials and Methods
 
Cells and Reagents
 
Mouse aortic endothelial cells (Bastaki et al., 1997), EaHy926, Phoenix
ecotropic packaging cell line (provided by Dr. G. Nolan, Stanford Univer-
sity, Palo Alto, CA), and NIH 3T3 cells were grown in DME 10% FCS
(Hyclone) in 10% CO
 
2
 
. The pBABE vector was provided by Dr. H. Land
(ICRF, London, UK), and pBKCMV and pGBT9 were acquired from
Stratagene and CLONTECH Laboratories, Inc. Angiostatin was gener-
ated from elastase-degraded human plasminogen as described previously
by O’Reilly et al. in 1994. Each batch of angiostatin was analyzed for en-
dotoxin using the limulus assay (BioWhittaker).
 
Yeast Two-hybrid Screening
 
Manipulation of DNA was performed according to standard molecular bi-
ological protocols (Sambrook et al., 1989). The two-hybrid library screen
was performed according to the protocol of the manufacturer (CLON-
TECH Laboratories, Inc.). PGBT9 plasmid containing the Gal4-binding
domain together with kringle domains 1–4 bait was transformed with a hu-
man term placenta cDNA library cloned into a GAL4 activation domain
fusion vector (CLONTECH Laboratories, Inc.). About 2 
 
3 
 
10
 
6 
 
yeast
transformants were plated on synthetic complete medium but lacking his-
tidine, leucine, and tryptophan. 48–96 h later, 244 yeast colonies were
picked and assayed for
 
 
 
b
 
-galactosidase (
 
b
 
-gal) activity in 
 
o
 
-nitrophenyl
 
b
 
-D-galactopyranoside (ONPG)-containing medium. Plasmid DNA was
recovered from 37 double-positive colonies, and candidate clones were re-
transfected into a new yeast strain (Y190). Three clones retained activity
in the new yeast strain. Sequence analysis revealed that these were de-
rived from the same gene.
 
cDNA Cloning
 
The whole gene was isolated by screening 3 
 
3
 
 10
 
6 
 
clones from a placental
 
l 
 
phage cDNA library (Stratagene) using a Hinf1 fragment of the angio-
motin sequence derived from the yeast two-hybrid screen. Five indepen-
dent clones were isolated that overlapped with the probe. The 5
 
9
 
 sequence
was used to design gene-specific primers for 5
 
9
 
RACE PCR (Life Technol-
ogies) and used to clone the remaining sequence using mRNA from hu-
man umbilical vein endothelial cells (HUVECs).
 
mRNA Expression Analysis
 
Commercially obtained multiple human and fetal tissue blots (CLON-
TECH Laboratories, Inc.) were probed with a 1-kb Pst1 fragment of the 5
 
9
 
end of angiomotin. The blots were hybridized with ExpressHyb solution
according to the protocol of the manufacturer. Real time PCR analysis
was performed using TaqMan Reverse Transcription Reagent (PE Bio-
systems) with random hexamers as reverse transcription (RT) primers.
The reaction volume for the RT step was 100
 
 
 
m
 
l and the total RNA
amount was 1 
 
m
 
g/sample. The PCR reaction of 10 ng of cDNA was per-
formed using the following oligonucleotides: angiomotin forward primer
5
 
9
 
-GTTTGACCTGCAATCCAGACAA-3
 
9
 
, reverse primer 5
 
9
 
-CCCAG-
GATCTGAATGGGAGTT-3
 
9
 
, and TaqMan probe 5
 
9
 
-CAGATGGGC-
CTGTGTTCCACTCCAA-3
 
9
 
. The cycling protocol was as follows: 2 min,
50
 
8
 
C; 10 min, 95
 
8
 
C, 1 cycle, 15 s, 95
 
8
 
C; 1 min, 60
 
8
 
C, 40 cycles. The amount
of 18s RNA was quantified as an internal control. The results were related
to the EaHy926 sample that expressed the lowest levels of angiomotin.
 
Generation of Angiomotin-expressing Cell Lines
 
HeLa cells were transfected with angiomotin open reading frame cloned
into the pBKCMV expression vector (Stratagene). Cells were transfected
using Lipofectin according to the protocol of the manufacturer (Life
Technologies). Stable clones were selected by G418 selection. Phoenix
Ecotropic packaging cell line was transfected with the pBABE, pBABE-
green fluorescent protein (GFP), pBABE-angiomotin, or pBABE-angio-
motin GFP constructs using standard calcium phosphate coprecipitation.
The culture supernatant was added to mouse aortic endothelial (MAE) or
NIH 3T3 cells and incubated for 24 h. The retrofected cells were then se-
lected in 3 
 
m
 
g/ml puromycin (Sigma-Aldrich) for 2 wk.
 
Immunofluorescence and Immunohistochemistry
 
Recombinant glutathione 
 
S
 
-transferase (GST)-tagged peptide from the
BIG3 clones was used for production of rabbit antisera. Rabbit antisera
were affinity purified in three cycles in a thiopropyl-Sepharose 6B (Amer-
sham Pharmacia Biotech) column with covalently coupled immunizing
peptide. On the last cycle, the depleted serum was collected and saved for
use as a control for the affinity-purified antiserum. The specificity of the
purified antibodies was verified by immunoprecipitation and Western blot
analysis. For immunofluorescence studies, cells were fixed in 3.7% formal-
dehyde in PBS blocked in horse serum and incubated for 1 h with primary
antibodies. Antibody binding was detected with FITC-labeled anti–rabbit
antibodies (Dako). Negative controls included preimmune IgG fraction as
well as preincubation with the immunizing antigen. Images were collected
with a Hamamatsu CCD camera using the OPEN LAB software. For im-
munohistochemistry, placental tissue was fixed and sectioned according to
standard histological procedures. Sections were permeabilized by micro-
wave treatment in sodium citrate buffer. Sections were incubated over-
night with the primary antibody and positive staining was visualized with
horseradish peroxidase staining using the Vectastain detection kit accord-
ing to the protocol of the manufacturer (Vector Laboratories).
 
In Vitro Kinase Activity
 
In vitro FAK assays were essentially performed as described by Claesson
et al., 1998. Cells were lysed in 50 mM Tris-HCl, pH 7.5/150 mM NaCl/
0.5% Triton X-100/1 mM phenyl-methyl-sulfonyl-fluoride/10 mM NaF/1
mM sodium orthovanadate on ice, the nuclei were pelleted, and the super-
natants were subjected to immunoprecipitation with FAK monoclonal an-
tibodies (Transduction lab.). The resulting immunoprecipitates were incu-
bated in kinase buffer (10 mM Tris-HCl, pH 7.5/0.01% Triton X-100/10
mM MnCl2) in the presence of 
 
g
 
[
 
32
 
P]ATP (immune complex kinase as-
say). SDS/PAGE was performed in 7% or 10% linear polyacrylamide gel.
The gel was dried and radioactive signals were analyzed using a phospho-
imager (Molecular Dynamics).
 
In Vitro Angiogenesis Assays
 
Endothelial cell migration was studied in modified Boyden chambers con-
taining chemotaxis membranes with an 8
 
-
 
m
 
m pore size (Nucleopore)
which were coated with Collagen 1 (BioWhittaker) as described previ-
ously (Kundra et al., 1995). MAE cells were pretreated with angiostatin
for 60 min at the concentrations indicated. Cells were detached by
trypsinization, washed, and resuspended in serum-free medium containing
0.1% BSA. Approximately 30,000 cells were added to the upper compart-
ment of the Boyden chamber with or without the addition of angiostatin.
Medium containing 50 ng/ml basic fibroblast growth factor (bFGF) was
used as a chemoattractant and 0.1% mg/ml BSA was placed in the lower
chamber. After incubation at 37
 
8
 
C for 4 h, filters were fixed and stained
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
-gal, 
 
b
 
-galactosidase; bFGF, basic fibro-
blast growth factor; FAK, focal adhesion kinase; GFP, green fluorescent
protein; GST; glutathione 
 
S
 
-transferase; HUVEC, human umbilical vein
endothelial cell; MAE, mouse aortic endothelial; RT, reverse transcription. 
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with Mayers Hematoxylin (Sigma-Aldrich) and the cells attached to the
bottom side of the membrane were counted visually under the micro-
scope. The data were expressed as the total number of cells counted per
high power field. In the in vitro tube formation assays, 150 
 
m
 
l of Matrigel
matrix was added to each well of an 8-well chamber slide and incubated at
37
 
8
 
C for 30 min to allow for gel formation. MAE cells were preincubated
with 5 
 
m
 
g/ml angiostatin before being plated on Matrigel (Becton Dickin-
son) at 2 
 
3
 
 10
 
5
 
 cells/well, and incubated in 10% CO
 
2
 
 at 37
 
8
 
C for 16 h.
Tubes were photographed at 40
 
3
 
 magnification and quantified tubes us-
ing the caliper available in the OPENLAB program. The average tube
length was then multiplied with the total number of tubes.
 
Results
 
Identification of a Kringle Domain 1–4 Binding Protein 
by Yeast Two-hybrid Screening
 
We generated a Gal4-binding domain fusion protein con-
taining the kringle domains 1–4 of angiostatin. This fusion
protein was expressed in yeast and did not activate the His
or
 
 
 
b
 
-gal reporter genes when expressed alone or in combi-
nation with control constructs (Fig. 1, A and B). Approxi-
mately 2 
 
3
 
 10
 
6
 
 clones from a human term placenta cDNA
library were screened with the angiostatin-Gal4 construct.
Screening under selective conditions (His
 
2
 
, Leu
 
2
 
, and
Trp
 
2
 
) generated 37 positive clones in the CG1945 yeast
strain. 7 of the 37 clones displayed high 
 
b
 
-gal activity after
incubation with ONPG at 30
 
8
 
C for 2 h. The DNA from the
colonies that contained high 
 
b
 
-gal activity was purified
and retransfected into yeast strain Y190. Three of the
seven of the colonies retained activity in the new yeast
strain. Sequence analysis revealed that these three clones
were derived from the same gene, and the yeast-derived
sequence was subsequently named BIG3. Binding of the
BIG3 peptide to angiostatin was verified by coimmuno-
precipitation of angiostatin with recombinant GST-tagged
 
BIG3 domain of angiomotin (Fig. 1 C). Angiostatin bind-
ing to BIG3 was visualized with antibodies against kringle
domains 1–4 by Western blot.
We cloned and sequenced the whole gene by screening
a placenta cDNA phage library with the yeast-derived se-
quence as a probe in combination with the 5
 
9
 
RACE PCR
technique as described in Materials and Methods. The
angiomotin cDNA genomic sequence data are avail-
able from Genbank/EMBL/DDBJ under accession nos.
AF286598 and NT_011819. The cDNA contained a 2,025-
bp open reading frame predicted to encode a 675 amino
acid protein of an estimated molecular mass of 72 kD
(Fig. 2, A and B). Due to its expression in endothelial
cells and its effect on cell motility, we named this protein
angiomotin. The amino acid sequence did not appear to
contain any signal sequence that is usually found in mem-
brane receptors or secreted proteins. This is comparable
with other plasminogen- or angiostatin-binding proteins
such as alpha enolase, annexin II, or the more recently
identified angiostatin-binding protein, ATP synthase (Miles
et al., 1991; Das et al., 1994; Hajjar et al., 1996; Moser et
al., 1999). All these proteins lack a signal peptide but still
bind plasminogen or angiostatin on the endothelial cell
surface.
Figure 1. Yeast two-hybrid
screening for angiostatin-
binding proteins in a human
placenta cDNA library. (A)
Yeast transfected with the
angiostatin-Gal4 binding
domain and BIG3-Gal4 acti-
vation domain grow under
growth-restricted conditions
(2Leu,  2His,  2Trp) and
in the presence of 50 mM
3-amino-1, 2,4-triazol. No
growth was detected in
yeast transfected with both
the angiostatin-Gal4 binding
domain and the Gal4 activa-
tion domain, or the Gal4
binding domain and the
BIG3-Gal4 activation do-
main. The p53-Gal4 binding
domain and SV40LT-Gal4
activation domain were used
as positive controls. (B) The
table shows the activity of the
nonselectable  b-gal marker in yeast cells transfected with an-
giostatin-Gal4 binding and the BIG3-Gal4 activation domain
and controls. (C) Binding of the 421 amino acid BIG3 sequence
derived from yeast two-hybrid screening was verified by co-
precipitation of GST-BIG3 with angiostatin.
Figure 2. (A) The amino acid sequence of angiomotin. The
amino acid sequence of the clone derived from the yeast two-
hybrid screening is underlined. (B) Genomic organization of
the angiomotin gene, size of cDNA, and the open reading frame
(ORF). The Genbank accession number for the angiomotin
cDNA genomic sequence data are available from GenBank/
EMBL/DDBJ under accession nos. AF286598 and NT_011819. 
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Binding of Angiostatin to Angiomotin
 
Next we assessed whether the expression of angiomotin in
cells in vitro would confer binding of fluorescein-labeled
angiostatin. In our experience, iodination of angiostatin
results in loss of activity whereas activity can be retained
when fluorescein labeling (FITC) is used (data not
shown). Primary bovine endothelial cells were incubated
with FITC-angiostatin for 60 min at 4
 
8
 
C before incubation
at 37
 
8
 
C for 15 min. Incubation at 37
 
8
 
C resulted in aggrega-
tion and internalization of angiostatin (Fig. 3). This pat-
tern of internalization is not detected in fibroblasts where
 
angiostatin only binds to the extracellular matrix. HeLa
cells were used for binding experiments, as they do not ex-
press angiomotin and exhibit little or no background an-
giostatin binding (Fig. 3). HeLa cells transfected with an-
giomotin bound and internalized angiostatin in a similar
pattern to that of endothelial cells whereas vector control
cells were negative. In addition, internalized FITC-
angiostatin colocalized with angiomotin in intracellular
vesicles (Fig. 3, bottom).
 
Angiomotin Expression In Vivo and In Vitro
 
We investigated the expression of angiomotin mRNA by
Northern blot analysis of mRNA derived from fetal and
adult human tissues. Hybridization with a 1-kb probe from
nucleotides 953–2,152 showed positive hybridization in
both fetal and adult tissues (Fig. 4 A). Two mRNA bands
with approximate sizes of 6.5 and 7.5 kb showed the most
abundant expression in placenta and skeletal muscle but
were detectable in all analyzed tissues. We also analyzed
the expression of Angiomotin mRNA in 15 different cell
lines by real time PCR. Highest expression could be de-
tected in human dermal microvascular and HUVECs (Ta-
ble I). To study angiomotin protein expression in vivo, we
raised a polyclonal antiserum directed against the recom-
binant protein that was derived from the sequence identi-
fied from the initial yeast two-hybrid clone. The resulting
antiangiomotin serum was subsequently affinity purified
against the immunizing peptide over an affinity column.
The serum and affinity-purified antibodies detected a pro-
tein with a molecular mass of 75 kD in angiomotin-trans-
fected NIH 3T3 cells but not in cells transfected with vec-
tor alone (Fig. 4 B).
Immunohistochemical analysis of human term placental
sections revealed positive staining in the endothelium of
larger vessels as well as in capillaries of microvilli (Fig. 4
Figure 3. Binding of FITC-labeled angiostatin to living cells in
culture. Cells were incubated with 10 mg/ml FITC-labeled an-
giostatin at 48C for 60 min. The cells were placed in 378C incubator
15 min before washing in PBS and fixation in 3.7% formaldehyde.
Angiostatin binds to and becomes internalized in bovine micro-
capillary endothelial (BME) cells resulting in a patchy staining of
endosomes (top left). In contrast, angiostatin binds to the matrix
of human fetal fibroblasts but is not internalized (top right).
HeLa cells transfected with angiomotin bind and internalize an-
giostatin in a similar pattern to that of endothelial cells (middle
left). HeLa-Ctrl cells are transfected with an empty vector and
were negative for angiostatin binding (middle right). The bottom
panel shows colocalization of FITC-angiostatin (ang.) with angio-
motin during internalization after surface binding to HeLa cells
transfected with angiomotin. Angiomotin was visualized by im-
munofluorescent staining using immunoaffinity-purified rabbit
polyclonal antibodies against angiomotin as described in Materials
and Methods. Bars, 10 mm.
 
Table I. 
 
Real Time RT-PCR Analysis of Angiomotin 
Expression in Various Cell Lines
 
Tissue
Angiomotin/18s 
mRNA ratio
 
Primary cells
Dermis H. dermal MVEC 12561
Placenta HUVEC 320
Dermis H. dermal fibroblasts 6
Cell lines
Lung H460 18
Ovarian A2780 67
Melanoma A375 87
Cervical HELA 4
Prostate DU145 30
Bladder ECV304 166
Colon HT29 28
Lymphoid CEM 6
Erythroid/Myeloid K562 3
Lymphoid Jurkat 2
myeloid THP-1 9
EC/epithelial hybrid EaHy926 1
 
Angiomotin mRNA levels were quantified in 10 ng cDNA generated by RT using
random hexamers. The result shows the expression of angiomotin relative to EaHy926
cells that showed the lowest level of expression of the target. The values are
represented as the ratio of angiomotin/18s mRNA. EC, endothelial cell; H., human;
MVEC, microvascular endothelial cell. 
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C). In addition, positive staining was also detected in ex-
travillous cytotrophoblasts (data not shown). We also ana-
lyzed the angiomotin expression in tumor vessels of Kapo-
sis sarcoma and vessels in adjacent normal tissue (Fig. 4
D). Angiomotin protein was detected in the endothelial
cells of vessels within the tumor but not in the blood ves-
sels of the surrounding normal dermal tissue.
 
Angiomotin Localizes to Lamellipodia of Migrating 
Endothelial Cells
 
Next we assessed the subcellular localization of Angiomo-
tin in transfected cells. The angiomotin open reading
frame was fused to GFP in the COOH terminus. Angio-
motin was expressed in NIH 3T3 cells using a retroviral
expression vector. The cellular localization differed de-
pending on whether cells were migrating or not. In migrat-
ing cells, angiomotin localized to the leading edge of the
lamellipodia of the migrating cell. Double staining with
antibodies against FAK showed overlapping localization
of these proteins in migratory cells (Fig. 5, a and b). We
also examined the distribution of endogenous angiomotin
in human umbilical cord endothelial cells. Cells were incu-
bated with angiomotin serum and rhodamine-labeled
phalloidin in order to visualize F-actin. The angiomotin
antibodies stained the leading edge of migrating cells (Fig.
5 c) and peripheral as well as circular ruffles in spreading
cells. Angiomotin overlaps with F-actin staining in these
structures, whereas no positive angiomotin staining was
detected in stress fibers (Fig. 5, e and f).
 
Angiostatin Induces FAK Activity in
Angiomotin-transfected Cells In Vitro
 
Previous studies have demonstrated that angiostatin in-
duces FAK activity in in vitro assays (Claesson-Welsh et
al., 1998). This is, to our knowledge, the only reported sig-
naling pathway that is affected by angiostatin. To assess
the effect of angiomotin on FAK activity, we transfected
angiomotin into the human cell line EaHy926 (derived
from a fusion hybrid between HUVECs and a carcinoma
cell line) or into the immortalized MAE cell line. Expres-
sion of endogenous angiomotin was not detectable by RT-
PCR analysis in neither of these two cell lines (data not
Figure 4. Angiomotin is expressed in endothelial cells in vivo. (A) Northern blot analysis of angiomotin expression in fetal and adult
human tissues. 2 mg of poly A1 RNA was analyzed for expression of angiomotin using a 1-kb probe from the 59 region. Two detect-
able transcripts were detected in both fetal and adult tissues (multitissue blot from CLONTECH Laboratories, Inc.; H, heart; Br,
brain; Pl placenta; Lu, lung; Li, liver; Ki, kidney; Pa, pancreas; M, marker). (B) Western blot analysis using immunoaffinity-purified
rabbit polyclonal antibodies against angiomotin. The antibodies detected a band with an approximate molecular mass of 75 kD in angio-
motin-transfected NIH 3T3 (Am.) cells but not in the vector (vect.) control. (C) Immunohistochemical localization of ABP-1 protein in
human placenta. Paraffin-embedded placental tissue from term placenta was stained with immunoaffinity-purified angiomotin poly-
clonal antibodies. (C, a) Shows angiomotin protein in endothelium of larger vessels in a placental villus. (C, b) Immunostaining using a
monoclonal antibody against CD34, an endothelial marker. (C, c) Detection of angiomotin protein in capillaries of placental microvilli.
(C, d) IgG negative control. (D) Expression of angiomotin in a dermal Kaposis sarcoma. (D, a) Shows angiomotin staining of a blood
vessel within the Kaposis lesion. (D, b) CD34 staining of a consecutive section of D, panel a. (D, c) Angiomotin-negative dermal blood
vessel (arrow) in the normal tissue adjacent to the Kaposis lesion. (D, d) Same as D, panel c, but stained with CD34. D, panels e and f,
are negative controls stained with nonimmune rabbit IgG as a negative control. Bars, 40 mm. 
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shown). Addition of angiostatin to angiomotin-transfected
cells increased the in vitro kinase activity of FAK within
1 h (Fig. 6, A and B). By contrast, no effect of angiostatin
was detected in cells transfected with the empty vector.
 
Angiostatin Inhibits Migration and Tube Formation of 
ABP-1 Transfected Cells
 
The localization of angiomotin in the leading edge of mi-
grating cells and the effect of angiostatin on FAK kinase
activity in angiomotin-transfected cells, suggested that an-
giomotin might play a role in endothelial cell migration.
To test this hypothesis, we studied the effect of angiomotin
expression in an angiomotin-negative immortalized MAE
cell line. MAE cells were infected with ecotropic retrovi-
rus expressing full-length angiomotin or vector alone.
Polyclonal cells were selected by puromycin treatment in
order to remove noninfected cells. The effect of angiomo-
tin on cell migration was tested in a modified Boyden
chamber. Analysis of spontaneous migration in the ab-
sence of chemoattractant showed that angiomotin cells
consistently exhibited a higher random migration than the
vector control cells (Fig. 7 A). We then tested whether an-
giostatin had any effect on the increased migratory rate of
the MAE-angiomotin cells. Cells were preincubated with 5
 
m
 
g/ml of angiostatin for 1 h before being added to the mi-
gration chamber. Angiostatin did not affect the random or
bFGF-induced migration of the control cells. In contrast,
angiostatin reduced the motility of MAE-angiomotin cells
to background levels (Fig. 7 B) The inhibition of cell mi-
gration was dose dependent with maximal inhibition esti-
mated at 500 ng/ml angiostatin (Fig. 7 C).
To further explore the role of angiomotin in mediating
angiostatin inhibition of angiogenesis, we studied the effect
of angiostatin on the formation of vascular structures in the
matrigel tube formation assay. No detectable difference be-
tween angiomotin- and vector-transfected MAE cells in the
capacity to form tubes in vitro could be detected (Fig. 8 A).
However, pretreating the cells for 16 h with angiostatin in-
hibited tube formation and caused a 90% inhibition of total
tube length (Fig. 8, A and B). This effect was specific for
cells transfected with angiomotin, whereas angiostatin did
not affect tubulogenesis in control cells.
 
Discussion
 
Angiostatin was one of the first tumor-generated angio-
genesis inhibitors to be identified. The mechanisms of ac-
tion appears to be highly specific, as angiostatin inhibits
migration and induces apoptosis specifically in endothelial
cells in vitro and interferes with blood vessel formation in
vivo. Here we report the identification of angiomotin, a
novel protein mediating angiostatin inhibition of migra-
tion and tube formation of endothelial cells. We used the
yeast two-hybrid system to identify angiostatin-binding
peptides in a human placental cDNA library. This screen-
ing procedure has been widely used to identify protein–
protein interactions such as proteins that interact with the
cytoplasmic parts of receptors. However, it has also been
Figure 5. Subcellular localization of transfected and endogenous
angiomotin. GFP-tagged angiomotin was expressed in NIH 3T3
cells using a retroviral expression system. Colocalization of GFP-
angiomotin (a) with FAK (b) in the extending lamellipodium. (c)
Immunofluorescence staining with a polyclonal antibody against
angiomotin shows similar localization of endogenous angiomotin
in a migrating HUVEC. (d) Control IgG from the same immunized
animal. e and f shows the localization of angiomotin (e) to actin
ruffles (f) and focal complexes in spreading HUVECs as visualized
by phalloidin staining (arrows). Bars, 10 mm.
Figure 6. Angiostatin induces FAK activity in vitro in cells
transfected with angiomotin. (A) Angiomotin-negative EaHy926
or (B) MAE cells were transfected with angiomotin or empty
vector. Cells were stimulated with angiostatin at the indicated
time points. FAK was immunoprecipitated and subjected to in
vitro kinase analysis as described in Materials and Methods.
Arrows indicate the localization of p125 FAK. 
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shown to be a useful tool to analyze the interactions of ex-
tracellular ligands and their receptors (Zhu and Kahn,
1997). The sequence encoding the angiostatin-binding do-
main of angiomotin was identified in three independent
clones after screening a placental cDNA library with the
K1–4 domains of angiostatin. The amino acid sequence was
rich in alanine (40%) and proline (20%). The proline/ala-
nine rich sequence included 4 (PXXP) motifs which may be
potential binding sites for Src homology 3 domains which
may be found in a diverse group of signal-transducing mole-
cules (Sudol, 1998). The angiomotin amino acid sequence
did not appear to contain any of the signal sequences that
are normally found in membrane receptors or secreted pro-
 
teins. This is in analogy with other plasminogen- or angiosta-
tin-binding proteins such as alpha enolase, annexin II, or the
more recently identified angiostatin-binding protein, ATP
synthase (Miles et al., 1991; Das et al., 1994; Hajjar et al.,
1996). These proteins lack the endoplasmic reticulum target-
ing peptide but are still localized to and are able to bind plas-
minogen or angiostatin on the endothelial cell surface.
The expression of angiomotin in the endothelium was
verified by immunohistochemical staining of placental ves-
sels. In the human term placenta, positive staining was de-
tected in larger vessels as well as in capillaries. In addition,
positive staining could also be detected in cytotrophoblasts,
a cell type characterized by its ability to invade the en-
dometrium and form a transitional circulatory system dur-
ing early embryogenesis. Interestingly, these cells have
been shown to express other “endothelial cell–specific”
proteins such as the vascular endothelial growth factor
(VEGF)-receptor 1 and tyrosine kinase with immunoglobin
and EGF homology domains (TIE)-2 (Ahmed et al., 1995;
Dunk et al., 2000). We also analyzed the expression pattern
of angiomotin in Kaposis sarcoma lesion, a tumor with en-
dothelial origin. Positive staining could be detected in ves-
sels infiltrating the tumor. Interestingly, dermal capillaries
in adjacent normal tissue in the same section were negative,
thus indicating that there is a differential expression of an-
giomotin in vessels of normal and pathological tissues.
Figure 7. Migration of MAE cells transfected with angiomotin or
with the vector alone was studied in the modified Boyden chamber
assay. (A) Analysis of spontaneous migration in the absence of
chemotactic factor at different time points after start of the experi-
ment. A higher number of angiomotin-expressing cells are migrat-
ing through the filter at all time points. Vertical axis, cells migrated
per high power field (HPF). (B) Effect of angiostatin on migration
of MAE-angiomotin and MAE vector cells with or without stimu-
lation with bFGF. Cells were pretreated for 1 h with angiostatin as
indicated. (C) Dose response of angiostatin-mediated inhibition of
migration of angiomotin-transfected MAE cells. All samples were
performed in quadruplicates (error bars 5 SD).
Figure 8. (A) Angiostatin inhibits tube formation of angiomotin-
transfected cells plated on matrigel. MAE-vector and MAE-
angiomotin transfected cells were pretreated with 5 mg/ml an-
giostatin for 16 h before trypsinization and plating on matrigel.
Images show tube formation 16 h after seeding on matrigel
(Bar, 130 mm). (B) Total tube length formed in the presence or
absence of angiostatin. The data represent the average from
three independent experiments (error bars 5 SD). 
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The endothelial cell migration assay has proven to be a
consistent predictor of inhibition of neovascularization in
vivo. Indeed, angiostatin, endostatin, and thrombospondin
all inhibit endothelial cell migration in vitro (Good et al.,
1990; Ji et al., 1998; Yamaguchi et al., 1999). Thrombo-
spondin is probably the best characterized angiogenesis in-
hibitor with regard to signaling pathways. It binds the
CD36 receptor and activates p38 mitogen-activated pro-
tein kinase (MAPK) via the src-related kinase, c-fyn
(Jimenez et al., 2000). In contrast, angiostatin-induced in-
hibition of angiogenesis is not dependent on either CD36
or c-fyn, as was recently shown in the mouse cornea angio-
genesis assay (Jimenez et al., 2000).
Our findings indicate a direct functional role for angio-
motin in endothelial cell migration, as angiomotin is lo-
cated in areas of actin reorganization and cells expressing
angiomotin migrate significantly faster than control cells.
Treatment of angiomotin-transfected cells with angiosta-
tin efficiently inhibited basal as well as bFGF-stimulated
migration of these cells, indicating that there is a direct
functional link between angiomotin and angiostatin. Fur-
thermore, we also showed that angiostatin reduced the to-
tal tube length generated by angiomotin-transfected cells
in the matrigel assay by 90%. However, endothelial cells
that are plated on Matrigel rapidly migrate to form cell ag-
gregates. Endothelial tubes are then extended between
these aggregates of cells. Angiostatin-treated MAE-angio-
motin cells remained primarily as single cells on the matri-
gel and did not form aggregates. This observation suggests
that angiostatin interferes with the early processes of tube
formation involving cell motility.
The angiomotin sequence provides little information into
exactly how it may be involved in mediating angiostatin in-
hibition of in vitro angiogenesis. The lack of a signal pep-
tide and transmembrane domain argues that angiomotin
does not act as a typical membrane receptor. The NH
 
2
 
-ter-
minal coil–coil domain as well as the proline rich sequences
in the angiostatin-binding domain suggest that angiomotin
forms protein complexes. Considering the stimulatory ef-
fect of angiomotin on endothelial cell migration, we specu-
late that angiostatin antagonizes angiomotin function by in-
hibiting the formation of complexes with other proteins.
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